BACKGROUND: Measurement of circulating insulin may improve the classification and management of diabetes mellitus and assist in treating people with insulin resistance. METHODS: A work group convened by the American Diabetes Association evaluated results for a panel of 39 single donor sera measured by 10 commercial insulin methods from 9 manufacturers against an isotope dilution-liquid chromatography/tandem mass spectrometry (IDMS) measurement procedure calibrated using purified recombinant insulin. We used a candidate primary (pure substance) reference material, pooled serum, and single donor sera to evaluate approaches to achieve improved agreement of results between the routine and reference measurement procedures. RESULTS: Four of 10 methods had >or=95% of individual serum results within 32% of the IDMS concentrations. However, the bias vs IDMS was more than 15.5% for 7 of 10 methods in 36%-100% of individual samples. A purified recombinant insulin preparation used as a common calibrator did not improve harmonization of results among routine methods but was not used as instructed by all participants. Calibration using serum pools achieved bias <15.5% for nearly all results in the concentration range covered by the pools (>60 pmol/L). Calibration using a panel of individual sera was the most effective to improve harmonization of results over the full measuring range. CONCLUSIONS: Agreement among methods can be improved by establishing traceability to the IDMS procedure using a panel of native sera. Pooled sera may be useful as trueness control materials. The usefulness of the pure insulin primary reference material [candidate reference material for insulin (cRMI)] requires clarification of protocols used by manufacturers.
BACKGROUND: Measurement of circulating insulin may improve the classification and management of diabetes mellitus and assist in treating people with insulin resistance. METHODS: A work group convened by the American Diabetes Association evaluated results for a panel of 39 single donor sera measured by 10 commercial insulin methods from 9 manufacturers against an isotope dilution-liquid chromatography/tandem mass spectrometry (IDMS) measurement procedure calibrated using purified recombinant insulin. We used a candidate primary (pure substance) reference material, pooled serum, and single donor sera to evaluate approaches to achieve improved agreement of results between the routine and reference measurement procedures. RESULTS: Four of 10 methods had >or=95% of individual serum results within 32% of the IDMS concentrations. However, the bias vs IDMS was more than 15.5% for 7 of 10 methods in 36%-100% of individual samples. A purified recombinant insulin preparation used as a common calibrator did not improve harmonization of results among routine methods but was not used as instructed by all participants. Calibration using serum pools achieved bias <15.5% for nearly all results in the concentration range covered by the pools (>60 pmol/L). Calibration using a panel of individual sera was the most effective to improve harmonization of results over the full measuring range. CONCLUSIONS: Agreement among methods can be improved by establishing traceability to the IDMS procedure using a panel of native sera. Pooled sera may be useful as trueness control materials. The usefulness of the pure insulin primary reference material [candidate reference material for insulin (cRMI)] requires clarification of protocols used by manufacturers.
Authors: Jeff Cobb; Walter Gall; Klaus-Peter Adam; Pamela Nakhle; Eric Button; James Hathorn; Kay Lawton; Michael Milburn; Regis Perichon; Matthew Mitchell; Andrea Natali; Ele Ferrannini Journal: J Diabetes Sci Technol Date: 2013-01-01
Authors: David B Sacks; Mark Arnold; George L Bakris; David E Bruns; Andrea Rita Horvath; M Sue Kirkman; Ake Lernmark; Boyd E Metzger; David M Nathan Journal: Diabetes Care Date: 2011-06 Impact factor: 19.112
Authors: Todd Castleberry; Christopher Irvine; Sarah E Deemer; Matthew F Brisebois; Ryan Gordon; Michael D Oldham; Anthony A Duplanty; Vic Ben-Ezra Journal: Eur J Appl Physiol Date: 2019-05-11 Impact factor: 3.078
Authors: K W ter Horst; P W Gilijamse; K E Koopman; B A de Weijer; M Brands; R S Kootte; J A Romijn; M T Ackermans; M Nieuwdorp; M R Soeters; M J Serlie Journal: Int J Obes (Lond) Date: 2015-07-09 Impact factor: 5.095
Authors: W Greg Miller; Jeffrey Budd; Neil Greenberg; Cas Weykamp; Harald Althaus; Heinz Schimmel; Mauro Panteghini; Vincent Delatour; Ferruccio Ceriotti; Thomas Keller; Douglas Hawkins; Chris Burns; Robert Rej; Johanna E Camara; Finlay MacKenzie; Eline van der Hagen; Hubert Vesper Journal: Clin Chem Date: 2020-06-01 Impact factor: 8.327
Authors: Myrlene A Staten; Michael P Stern; W Greg Miller; Michael W Steffes; Scott E Campbell Journal: Diabetes Care Date: 2010-01 Impact factor: 19.112